VistaGen Therapeutics, Inc.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US92840H4002

USD

0.61

-0.01 (-0.99%)

Mar 25

NAS

View all stocks in this country

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

VistaGen Therapeutics, Inc.

ImmuCell Corp.

HOOKIPA Pharma, Inc.

ImmunoPrecise Antibodies Ltd.

Solid Biosciences, Inc.

Cognition Therapeutics, Inc.

Gain Therapeutics, Inc.

Mainz Biomed NV

Viracta Therapeutics, Inc.

CytoMed Therapeutics Ltd.

OKYO Pharma Ltd.

Why is VistaGen Therapeutics, Inc. ?

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -78.82%, its profits have fallen by -70.6%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -5.36% over the previous quarter and currently hold 14.52% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 13.68% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -78.82% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is VistaGen Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

VistaGen Therapeutics, Inc.

-79.03%

-0.75

111.66%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.33%

EBIT Growth (5y)

-222.61%

EBIT to Interest (avg)

-38.45

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.14

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.02%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

70.54%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.49

EV to EBIT

0.51

EV to EBITDA

0.51

EV to Capital Employed

3.62

EV to Sales

-34.38

PEG Ratio

Dividend Yield

ROCE (Latest)

715.68%

ROE (Latest)

-132.56%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -21.26% (YoY

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for VistaGen Therapeutics, Inc.

Raw Material Cost

Fallen by -21.26% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales